Published on
Last updated on
Fast-Track Approval Updates in October & November 2020

During the past month, the NMPA (National Medical Device Evaluation) and CMDE (Center for Medical Device Evaluation) were actively involved in facilitating the fast-track approvals for medical devices in the Chinese market.
Procedure for Prioritized Review and Approval of Medical Devices
On October 29, the CMDE announced (No.22 – 2020) an additional set of specifications for medical devices applying for fast-track approval via the Procedure for Prioritized Review and Approval of Medical Devices.
The specifications are listed in the following:
- The product is urgently needed for clinical use and there are no similar devices existing in the market yet.
- The product is expected to diagnose and treat serious life-threatening diseases
- There is currently no effective way to diagnose or treat the disease in China
- The principle of operating the device is clear and finalized with a basic theoretical and experimental approach
- There is sufficient clinical trial data to perform a valid assessment and to prove the product’s ability or provide clinical value
The announcement also addressed some additional information required in the basic dossier submission:
- Clinical evaluation of the product’s condition and setting while operating
- The clinical value of the product with data information to support
- Evidence to show that only this product in the market has the capability to diagnose or treat the disease effectively
- Applicants should refer to the Guidelines for Conditional Approval for Marketing of Medical Devices for dossier submission
Emergency Approval Procedure for Medical Devices
On November 5, the NMPA announced that 2 COVID-19 detection reagent products have been registered in China via the Emergency Approval Procedure for Medical Devices. According to the announcement, a total of 51 products had been registered via the procedure in 2020:
- 24 new coronavirus nucleic acid detection reagents
- 25 antibody detection reagents
- 2 antigen detection reagents
Special Review Procedure for Innovative Medical Devices
On November 2, the CMDE announced that 7 domestic products and 1 overseas product (Medtronic, Inc) had been approved to apply for the Special Review Procedure for Innovative Medical Devices.
On November 11, the NMPA announced that 3 domestic products had been registered via the Special Review Procedure for Innovative Medical Devices:
- Home test kits for colon cancer (New Horizon Health Ltd.)
- CT diagnostic software (Yukun (Beijing) Network Technology Co., Ltd.)
- Drug Eluting Balloon PTA Catheter (Zylox Medical Device Co.)
By Jacky Li. Contact Cisema if you would like to learn more.
Connect with Cisema
With more than 20 years of experience and a team of over 100 specialists, Cisema helps global companies achieve compliance across Asia Pacific with confidence and accelerate market entry.
Stay Informed with Monthly News and Analysis
Stay informed with the latest regulatory changes, expert insights, and market opportunities across APAC, delivered straight to your inbox.



